SCHEMBL7041691

SCHEMBL7041691

COC(=O)c1cc(-c2cc(OC)ccc2OC)ccc1NC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
HDAC1 Q13547 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
KDM4E B2RXH2 2/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KCNH2 Q12809 1/20 0.48
KCNMA1 Q12791 1/20 0.47
PPARG P37231 5/20 0.47
TP53 P04637 2/20 0.47
PPARA Q07869 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
PYGL P06737 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
STIM1 Q13586 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7037066 0.92 PPARG (0.57) MAPTSMN1; SMN2HDAC1HDAC8HDAC6
Lithium Ion SCHEMBL7041664 0.90 PPARG (0.59) MAPTSMN1; SMN2HDAC1HDAC8HDAC6
SCHEMBL7039787 0.87 HDAC8 (0.50) MAPTSMN1; SMN2HDAC1HDAC8HDAC6
SCHEMBL7034504 0.85 PPARG (0.54) MAPTSMN1; SMN2HDAC1HDAC8HDAC6
SCHEMBL7039680 0.80 PPARG (0.59) MAPTSMN1; SMN2HDAC1HDAC8HDAC6
SCHEMBL7040693 0.79 PPARG (0.60) MAPTHDAC8HDAC6KDM4EPPARG
SCHEMBL7038522 0.79 PPARG (0.54) MAPTSMN1; SMN2HDAC1HDAC8HDAC6
SCHEMBL7034530 0.79 PPARG (0.56) MAPTSMN1; SMN2HDAC8KDM4EPPARG
SCHEMBL7037291 0.78 PPARG (0.52) MAPTSMN1; SMN2HDAC1HDAC8HDAC6
SCHEMBL7038586 0.78 PPARG (0.61) SMN1; SMN2HDAC8HDAC6KDM4EPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073862-A1 Compounds BIOVITRUM AB (SE) 2003-04-17 US disclosed
WO-2003004458-A1 NEW COMPOUNDS BIOVITRUM AB (SE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073862-A1 Compounds PPARG, PPARA, PPARD MAPT 4479/4885SMN1; SMN2 2475/4885HDAC1 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.